To the Editor:
Cardiac troponin is the marker of choice for evaluating myocardial injury (1 ) . High-sensitivity assays improve analytical detection limits, thereby allowing concentrations to be measured in the majority of healthy individuals. This capability allows an assessment of biologic variation (BV) 1 to determine what constitutes an important change in the cardiac troponin concentration, a critical metric for identifying acute events. Such an event is often a myocardial infarction, but any acute cardiac injury can cause increasing and/or decreasing values (1 ) . Accordingly, we evaluated BV for a recently developed high-sensitivity cardiac troponin I (hs-cTnI) assay (2 ) from Beckman Coulter. We performed this study with the same cohort used to define BV for the high-sensitivity cardiac troponin T (hs-cTnT) assay (3 ) and according to a protocol approved by our institutional review board.
For assessment of short-term BV, we collected blood into serum separator tubes (Becton Dickinson) at 0, 1, 2, 3, and 4 h, centrifuged the tubes, and stored the serum samples immediately at Ϫ70°C. Samples are stable under these conditions (2 ) . For the longterm study, samples were obtained biweekly for 8 weeks and processed similarly. After thawing the samples, we analyzed the samples without recentrifugation in duplicate on the Access analyzer (Beckman Coulter). The limit of blank for this assay is 1.03 ng/L, the limit of detection is 2.06 ng/L, the lowest concentration with an imprecision (CV) Ͻ10% is 8.66 ng/L, and the 99th percentile value for serum is 8.00 ng/L, as previously reported (2 ) . Reference change values (RCVs) were calculated as previously described (4 ) 
No participants had values below the limit of blank. tively]. The RCVs were ϩ45.2%/ Ϫ15.8% and 14.0%/Ϫ10.6% for short-term and long-term BV, respectively (Table 1 ). There were no significant differences between the sexes according to the t-test.
These results provide index data for a research hs-cTnI assay. The results are similar to those obtained for another hs-cTnI assay (4 ) but lower than those observed with the hs-cTnT assay (3 ). The high degree of BV in our hs-cTnT data has been suggested to be due to underlying cardiovascular comorbidities. The present data are more consistent with the hypothesis that the differences are related to differences in the precision of the assays at very low troponin concentrations.
These data add to the evidence-based information necessary to use BV as a metric to evaluate important changes and perhaps a more refined definition of acute cardiovascular events (1 ). 
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